References
- Reus VI. Mental disorders. Kasper DL, Fauci AS, Longo DL, Braunwald E, Hauser SL, Jameson JL. Harrison's principles of internal medicine, 16th New York: McGraw-Hill, 2005:2559–2560.
- Lieberman JA, Stroup TS, McEvoy JP for Clinical Anti-psychotic Trials of Intervention Effectiveness (CATIE) Investigators. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005; 353:1209–1223.
- Thomas S. Drug reference for FDA approved psychiatric drugs [monograph on the internet]. Quincy, Illinois: Neurotransmitter. net; 2009 [cited 2009 Feb 1]. Available from: http://www.neurotransmitter.net/drug reference.html.
- US Food and Drug Administration. 2004 safety alert on Zyprexa (olanzapine). Rockville, MD: US Food and Drug Administration MedWatch Programme, 2004. [cited 1 February 2009]. Available from URL: http://www.fda.gov/medWatch/SAFETY/2004/zyprexa.htm
- Loo H, Poirier-Littre MF, Theron M, Rein W, Fleurot O. Amisulpride versus placebo in the medium-term treatment of the negative symptoms of schizophrenia. Br J Psychiatry 1997; 170:18–22.
- Central Drugs Standard Control Organization. New drug approvals in India in 2006 [monograph on the internet]. New Delhi: Central Drugs Standard Control Organization; 2006 [cited 2008 Sep 20]. Available from: http://cdsco.nic.in/new_drugs_app6.html.
- Lecrubier Y, Quintin P, Bouhassira M, Perrin E, Lancrenon S. The treatment of negative symptoms and deficit states of chronic schizophrenia: olanzapine compared to amisulpride and placebo in a 6-month double-blind controlled clinical trial. Acta Psychiatr Scand 2006; 114:301–302.
- Mortimer A, Martin S, Loo H, Peuskens J for the SOLIANOL Study Group. A double-blind, randomized comparative trial of amisulpride versus olanzapine for 6 months in the treatment of schizophrenia. Int Clin Psychopharmacol 2004; 19:63–69.
- American Psychiatric Association. Diagnostic and statistical manual of mental disorders, 4th Washington, DC: American Psychiatric Association, 2000.
- Overall JE, Gorham DR. The brief psychiatric rating scale. Psychol Rep 1962; 10:799–812.
- Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 1987; 13:261–276.
- Uppsala Monitoring Centre. The use of the WHO-UMC system for standardized case causality assessment [monograph on the internet]. Uppsala: Uppsala Monitoring Centre; 2005 [cited 2008 Jul 7]. Available from: http://www.who-umc.org/graphics/4409.pdf.
- Haro JM, Salvador-Carulla L. The SOHO (Schizophrenia Outpatient Health Outcome) study: implications for the treatment of schizophrenia. CNS Drugs 2006; 20:293–301.
- Coulouvrat C, Dondey-Nouvel L. Safety of amisulpride (Solian): a review of 11 clinical studies. Int Clin Psychopharmacol 1999; 14:209–218.
- Baldessarini RJ, Tarazi FI. Pharmacotherapy of psychosis and mania. Brunton LL, Lazo JS, Parker KL. Goodman and Gilman's the pharmacological basis of therapeutics, 11th New York: McGraw-Hill, 2006:461–487.